Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

McKeage K, Lyseng-Williamson KA

Open source

DOI
10.1007/s40267-018-0551-x
Published
2018
Container
Drugs & therapy perspectives : for rational drug selection and use
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40267-018-0551-x,
  title = {Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.},
  author = {McKeage K and Lyseng-Williamson KA},
  year = {2018},
  journal = {Drugs \& therapy perspectives : for rational drug selection and use},
  doi = {10.1007/s40267-018-0551-x},
  url = {https://doi.org/10.1007/s40267-018-0551-x}
}

RIS

TY  - JOUR
TI  - Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
AU  - McKeage K
AU  - Lyseng-Williamson KA
PY  - 2018
JO  - Drugs & therapy perspectives : for rational drug selection and use
DO  - 10.1007/s40267-018-0551-x
UR  - https://doi.org/10.1007/s40267-018-0551-x
ER  - 

APA

K, M., & KA, L. (2018). Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.. Drugs & therapy perspectives : for rational drug selection and use. https://doi.org/10.1007/s40267-018-0551-x

Source records